Analyst Price Targets — FDMT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 8, 2026 11:53 am | — | Goldman Sachs | $33.00 | $9.93 | TheFly | 4D Molecular price target lowered to $33 from $38 at Goldman Sachs |
| November 11, 2025 10:23 am | Gena Wang | Barclays | $33.00 | $10.17 | TheFly | 4D Molecular price target lowered to $33 from $38 at Barclays |
| October 31, 2025 1:20 pm | Mani Foroohar | Leerink Partners | $17.00 | $11.50 | StreetInsider | 4D Molecular Therapeutics (FDMT) PT Raised to $17 at Leerink Partners |
| October 21, 2025 1:11 pm | Lisa Walter | RBC Capital | $26.00 | $10.77 | StreetInsider | RBC Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT) |
| January 11, 2025 7:38 pm | Judah Frommer | Morgan Stanley | $6.00 | $5.52 | TheFly | 4D Molecular price target lowered to $6 from $8 at Morgan Stanley |
| September 19, 2024 8:14 am | Kostas Biliouris | BMO Capital | $40.00 | $13.28 | StreetInsider | BMO Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT) |
| September 19, 2024 8:06 am | Geulah Livshits | Loop Capital Markets | $39.00 | $13.31 | StreetInsider | Chardan Capital Markets Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT) |
| September 19, 2024 6:46 am | Matthew Caufield | H.C. Wainwright | $36.00 | $13.31 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT) |
| April 15, 2024 6:29 am | Lisa Walter | RBC Capital | $40.00 | $26.35 | StreetInsider | 4D Molecular Therapeutics (FDMT) PT Raised to $40 at RBC Capital |
| April 15, 2024 3:43 am | Gena Wang | Barclays | $45.00 | $26.35 | StreetInsider | Barclays Starts 4D Molecular Therapeutics (FDMT) at Overweight |
Latest News for FDMT
EMERYVILLE, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on July 14, 2026, the compensation committee of the Company's board of directors granted…
EMERYVILLE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced a podium presentation at the 44th Annual Scientific Meeting of the American Society of Retina…
EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that it has entered into a strategic credit facility agreement with Hercules Capital, Inc.…
EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced enrollment completion for 4FRONT-2, the second Phase 3 clinical trial in our global program,…
4D Molecular Therapeutics (FDMT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for FDMT.
U.S. House Trading
No House trades found for FDMT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.